The FDA granted accelerated approval to the programmed cell death receptor-1 agent dostarlimab-gxly (Jemperli, GlaxoSmithKline) for adults with mismatch repair–deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, who have progressed during or after prior treatment and lack satisfactory alternative treatment options.
The agency also approved the VENTANA MMR RxDx Panel as a companion diagnostic device to select patients with dMMR solid tumors for